| Ytd | -14.50% | |
| 1y | -65.93% |
| Open | 0.68 | Prev Close | 0.70 | Low | 0.66 | High | 0.69 | Mkt Cap | 17.27M |
| Vol | 67.14K | Avg Vol | 154.57K | EPS | -0.51 | P/E | -1.36 | Forward P/E | -2.27 |
| Beta | 1.58 | Short Ratio | 2.01 | Inst. Own | 0.97% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-08 | 50-d Avg | 0.76 | 200-d Avg | 0.89 | 1yr Est | 7.50 |
NRSN News
The planned submission follows alignment with Health Canada on the NDS pathway and is supported by a
Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in A
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction
First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reducti
First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reducti
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnol
PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease
CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS Expands i
Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil patents CAMBRIDGE
Financing led by CEO Alon Ben-Noon and CFO Or Eisenberg, alongside participation from an existing si
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN - Get Free Report) has been given a consensus rating of "
Patent Protection Through October 2042 Follows prior patent grants in the U.S. and Australia Further
Notifications have no immediate effect on the listing or trading of the Company's securities on Nasd
2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program i
CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Dr. Christian Lunetta to Present "From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2
The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent c
Analysts change outlook on top names, including initiations, upgrades, and downgrades. MSTR has a $1
CAMBRIDGE, Mass., March 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Shares of NeuroSense Therapeutics Ltd. (NASDAQ: NRSN - Get Free Report) traded down 14.7% during tra
CAMBRIDGE, Mass., Feb. 18, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Strengthens Global IP Portfolio for PrimeC Through 2042 CAMBRIDGE, Mass., Feb. 9, 2026 /PRNewswire/